Antibody · 고형암 (전체)

249개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved249 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleGregory DanielsPhase 2

nivolumab (Opdivo, IL-2 and Nivolumab)

Melanoma Stage Iv; Renal Cell Carcinoma, Metastatic · Melanoma Stage Iv

#MelanomaStageIv#Antibody#Phase2#monoclonal-antibody#RenalCellCarcinoma+2
Trials 1Status Discontinued
AntibodyLimited DatastaleImmuneering CorporationPhase 2

Treatment Group E (IMM-1-104 + pembrolizumab, IMM-1-104 + pembrolizumab (Treatment Group E))

Advanced Solid Tumor; Pancreatic Adenocarcinoma · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#monoclonal-antibody#PancreaticAdenocarcinoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleAssociazione Volontari Pazienti…Phase 3

INDUCTION CTx (TPF, INDUCTION CTx, INDUCTION CTx(TPF)+(RT+CETUXIMAB))

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#monoclonal-antibody#Associazione
Trials 1Status Active
AntibodyLimited DatastaleAstraZenecaPhase 1

durvalumab (Imfinzi, IPH5401 and Durvalumab)

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase1#monoclonal-antibody#AstraZeneca
Trials 1Status Discontinued
AntibodyLimited DatastaleMerckPreclinical

pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab (Immune Checkpoint Inhibitors, Immune Checkpoint Inhibitors ( pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab))

Esophageal Squamous Cell Carcinoma (ESCC) · Esophageal Squamous Cell Carcinoma (ESCC

#EsophagealSquamousCellCarcinomaE#Antibody#Preclinical#monoclonal-antibody#Merck
Trials 1Status Recruiting
AntibodyLimited DatastaleSir Run Run Shaw HospitalPhase 2

Ipalolimab and Tovorilimab (Ipalolimab and Tovorilimab)

dMMR/MSI-H-type Rectal Adenocarcinoma · dMMR/MSI-H-type Rectal Adenocarcinoma

#dMMRMSI-H-typeRectalAdenocarcino#Antibody#Phase2#monoclonal-antibody#dMMR+2
Trials 1Status Recruiting
AntibodyLimited DatastaleTianjin Medical University Canc…Phase 2

Iparomlimab and tuvonralimab (Iparomlimab and tuvonralimab)

HCC - Hepatocellular Carcinoma; Iparomlimab and Tuvonralimab Injection · mCRC

#mCRC#Antibody#Phase2#monoclonal-antibody#HCC-HepatocellularCarcinoma+2
Trials 1Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 1

administered with & without Cetuximab (Irinotecan, Irinotecan (administered with & without Cetuximab))

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#monoclonal-antibody#AstraZeneca
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 1

JS001+Bevacizumab (JS001+Bevacizumab)

Advanced Malignant Solid Tumors · Advanced Malignant Solid Tumors

#AdvancedMalignantSolidTumors#Antibody#Phase1#monoclonal-antibody#Roche
Trials 1Status Recruiting
AntibodyLimited DatastaleKeythera Pharmaceuticals (Austr…Phase 1

atezolizumab (Tecentriq, KF-0210, KF-0210 (dosage RP2D) + Atezolizumab, dosage RP2D)

Advanced Solid Tumor; Colorectal Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#monoclonal-antibody#ColorectalCancer+1
Trials 1Status Active
AntibodyLimited DatastaleKeythera Pharmaceuticals (Austr…Phase 1

atezolizumab (Tecentriq, KF-0210, dosage RP2D-1, KF-0210 (dosage RP2D-1) + Atezolizumab)

Advanced Solid Tumor; Colorectal Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#monoclonal-antibody#ColorectalCancer+1
Trials 1Status Active
AntibodyLimited DatastaleKeythera Pharmaceuticals (Austr…Phase 1

atezolizumab (Tecentriq, KF-0210, dosage RP2D-2, KF-0210 (dosage RP2D-2) + Atezolizumab)

Advanced Solid Tumor; Colorectal Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#monoclonal-antibody#ColorectalCancer+1
Trials 1Status Active
AntibodyLimited DatastaleGroupe Oncologie Radiotherapie …Phase 3

Ligufalimab (Ligufalimab)

Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) · Squamous Cell Carcinoma Head and Neck Ca

#SquamousCellCarcinomaHeadandNeck#Antibody#Phase3#monoclonal-antibody#Groupe
Trials 1Status Recruiting
AntibodyLimited DatastaleAbbViePhase 3

Livmoniplimab (Livmoniplimab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase3#monoclonal-antibody#AbbVie
Trials 1Status Recruiting
AntibodyLimited DatastaleMerus B.V.Phase 2

pembrolizumab (Keytruda, MCLA-158 + Pembrolizumab)

Advanced/Metastatic Solid Tumors; Colorectal Cancer · Advanced/Metastatic Solid Tumors

#AdvancedMetastaticSolidTumors#Antibody#Phase2#monoclonal-antibody#Advanced+3
Trials 1Status Recruiting
AntibodyLimited DatastaleMedImmune LLCPhase 2

durvalumab (Imfinzi, MEDI6469 Plus Durvalumab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#monoclonal-antibody#AggressiveB-cellLymphomas+1
Trials 1Status Discontinued
AntibodyLimited DatastaleMedImmune LLCPhase 2

MEDI6469 Plus Tremelimumab (MEDI6469 Plus Tremelimumab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#monoclonal-antibody#AggressiveB-cellLymphomas+1
Trials 1Status Discontinued
AntibodyLimited DatastaleMedImmune LLCPhase 2

MEDI6469 plus Rituximab (MEDI6469 plus Rituximab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#monoclonal-antibody#AggressiveB-cellLymphomas+1
Trials 1Status Discontinued
AntibodyLimited DatastaleMedivirPhase 2

pembrolizumab (Keytruda, MIV-818, MIV-818 (fostroxacitabine bralpamide) + pembrolizumab, fostroxacitabine bralpamide)

Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#IntrahepaticCholangiocarcinoma+1
Trials 1Status Active
AntibodyLimited DatastaleCentre Hospitalier Universitair…Phase 2

durvalumab (Imfinzi, MP0317 + Gemcitabine + Cisplatine + Durvalumab)

Advanced Biliary Tract Carcinoma · Advanced Biliary Tract Carcinoma

#AdvancedBiliaryTractCarcinoma#Antibody#Phase2#monoclonal-antibody#Centre
Trials 1Status Recruiting

8 / 13 pages

← PreviousNext →